Clinical Trials Logo

Cardiovascular Abnormalities clinical trials

View clinical trials related to Cardiovascular Abnormalities.

Filter by:

NCT ID: NCT02966028 Completed - Clinical trials for Cardiovascular Diseases

Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)

Start date: November 2016
Phase: Phase 2
Study type: Interventional

The primary objective is to assess the effect of 2 dose levels of SNF472 (300 mg and 600 mg) compared to placebo on the progression of coronary artery calcium volume score over a 12-month (52 weeks) period in ESRD patients on HD

NCT ID: NCT02910635 Completed - Clinical trials for Abnormalities, Cardiovascular

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

Start date: September 19, 2016
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to assess the corrected QT interval (QTc) effect of volanesorsen (ISIS 304801) administered as a 300 mg subcutaneous (SC) therapeutic and a 300 mg intravenous (IV; 2-hour infusion) supra-therapeutic dose relative to placebo in healthy adult male and female subjects.

NCT ID: NCT02894060 Completed - Clinical trials for Cardiovascular Abnormalities

A Study of Immunological Biomarkers as Predictors of Cardiovascular Events

BIOKID
Start date: June 2014
Phase: N/A
Study type: Interventional

Cardiovascular disease linked to atherosclerosis (e.g. infarcts, cerebro-vascular accidents) are one of the main causes of mortality in the general population. The recruitment of macrophages from the walls of the arterial lumen followed by unregulated capture of oxidated LDL (LDLox) leads to the accumulation of cholesterol esters and the formation of foamy cells characteristic of fatty streaks, the first phase of atherogenesis. These fatty streaks are rarely followed by clinical events, but can progress to complicated atheromatoses (calcification, rupture) resulting in the occurrence of various clinical events such as myocardial infarction and cerebro-vascular accidents (CVA). Once oxidated, LDL becomes immunogenic and induces anti-LDLox antibody production that could be markers of progression of atherosclerosis. During LDL oxidation, a multitude of specific oxidative epitopes (SOE) such as oxidated phospholipids (PLox) and malondialdehyde-lysine epitopes (MDA) are generated. In order to measure the level of markers in the blood, researchers developed a series of immunologic levels in vitro, using specific antibodies directed against well-defined epitopes. Recently, it was shown that Lp(a ) would be the preferred transporter of these PLox. In fact, several clinical studies show a strong correlation between PLox/apoB concentrations and Lp(a). This marker (PLox/apoB) predicts future morbidity and mortality due to cardiovascular diseases, including CVA, up to 15 years in advance, independent of all other known risk factors. CD36 is a scavenger receptor that recognizes LDLox, but more specifically PLox present in these lipoproteins .One soluble form of inflammatory CD36 (sCD36) was recently identified. In this study, only healthy volunteers were recruited in order to be able to establish normal serum ranges of different immunologic biomarkers.

NCT ID: NCT02616913 Completed - Clinical trials for Cardiovascular Abnormalities

Evaluation of the Cardiac Effects of a Novel Food Ingredient in Healthy Male Subjects

Start date: March 2013
Phase: N/A
Study type: Interventional

This study evaluates if a single oral dose of 150 mg of the novel food ingredient (AME001, R,R-monatin) does not have an effect on the Fridericia-corrected QT ECG interval (QTcF) exceeding 10 milliseconds (msec). Each subject will consume test article (150 mg), placebo, and moxifloxacin (400 mg; positive control) in each of 3 treatment periods.

NCT ID: NCT02555319 Completed - Clinical trials for Congenital Heart Defects

A Feasibility Study to Evaluate the Safety and Short-term Effectiveness of Transcatheter Pulmonary Valve (TPV)

Start date: August 26, 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and short-term effectiveness of implantation of Transcatheter Pulmonary Valve (TPV) for the treatment of congenital heart disease with pulmonary valve disease.

NCT ID: NCT02436317 Completed - Clinical trials for Hemodynamic Instability

Point of Care Ultrasonography

Start date: July 19, 2015
Phase: N/A
Study type: Interventional

This is a Prospective, Double-center, randomized clinical trial. The purpose of the trial is to evaluate the benefit of adding POC US to the management of inpatients admitted to the internal ward with respiratory, cardiovascular or hemodynamic abnormalities.

NCT ID: NCT02300207 Completed - Clinical trials for Cardiovascular Abnormalities

Electroacupuncture is Effective in Cardiac Deconditioning Induced by Head-down Bed Rest

Start date: July 2014
Phase: N/A
Study type: Interventional

To investigate the changes of cardiovascular function during short-term simulated weightlessness after electroacupuncture (EA) treatment.

NCT ID: NCT01820702 Completed - Body Weight Changes Clinical Trials

Short Term Bed Rest Study: Evaluation of the Use of Artificial Gravity, Induced by Short-arm Centrifugation

SAG
Start date: November 2010
Phase: N/A
Study type: Interventional

Randomized cross-over design with 10 male subjects and 3 campaigns to test whether the negative effects of bed rest (6º head-down tilt) on the various systems of the body and the consequences to health of simulated weightlessness can be counteracted by the use of a defined training programme.

NCT ID: NCT01811667 Completed - Clinical trials for Cardiovascular Abnormalities

Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations

vasca-LM
Start date: May 2012
Phase: Phase 3
Study type: Interventional

The phosphatidylinositol 3-kinase (PI3Kinase)/Protein Kinase B (AKT)/mammalian target of rapamycin (mTor) pathway plays a role on the development and the lymphatic-vascular organisations. The investigators want to study the efficacy and the safety of Rapamycin, an mTor inhibitor.

NCT ID: NCT01509456 Completed - Body Weight Changes Clinical Trials

The Effect of Potassium Bicarbonate on Bone and Several Physiological Systems During Immobilisation

NUC
Start date: February 2010
Phase: N/A
Study type: Interventional

Mainly due to the absence of gravitational forces in weightlessness, astronauts suffer from an increased bone loss- negatively affecting health and vitality during a mission. The development of effective countermeasures to this loss includes many different aspects like sports but also nutrition. Alkaline salts, abundant in fruits and vegetables, have shown to have positive effects on markers of bone turnover of postmenopausal women but also men and younger adults. With the current study the effects of a potassium bicarbonate supplementation added to a standardised, strictly controlled, definite diet of healthy, young men, should be verified within 21 days of 6°- HDT- Bedrest- the gold standard of simulating weightlessness within earthbound conditions.